Eversept Partners LP Sells 1,129,335 Shares of InflaRx (NASDAQ:IFRX)

Eversept Partners LP lowered its holdings in InflaRx (NASDAQ:IFRX) by 69.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 492,452 shares of the company’s stock after selling 1,129,335 shares during the quarter. Eversept Partners LP’s holdings in InflaRx were worth $1,216,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in IFRX. Walleye Capital LLC purchased a new stake in InflaRx in the 4th quarter valued at $51,000. Geode Capital Management LLC increased its stake in InflaRx by 32.8% in the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after buying an additional 11,900 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in shares of InflaRx by 20.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after buying an additional 19,000 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of InflaRx in the fourth quarter valued at approximately $1,576,000. 42.39% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on IFRX shares. Guggenheim raised their target price on InflaRx from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, March 26th. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of InflaRx in a research note on Friday, March 21st.

InflaRx Trading Up 7.5 %

InflaRx stock opened at $1.14 on Tuesday. The firm has a market capitalization of $76.53 million, a price-to-earnings ratio of -1.06 and a beta of 2.21. The firm has a 50 day simple moving average of $1.29 and a 200 day simple moving average of $1.83. InflaRx has a 1-year low of $0.82 and a 1-year high of $2.82.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. On average, equities research analysts forecast that InflaRx will post -1.04 EPS for the current year.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.